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In this chapter the theoretical basis of intraperitoneal ( lP) therapy, pracrical
implications such as obtaining access to the peritoneal cavity and cl inical ut i l i ty are
discussed. Because ovarian cancer remains confined to the peritoneal cavity for most of i ts
natural course, i t  was proposed in the early 70's that IP chemotherapy could be employed
to increase the exposurc of tumor cel ls to chemotherapeutic agents and thereby increase
responses ar-rd survival.  Since that t ime, we have learned some valuable lessons. First ly, lP
therapy it.t ovarian cancer is f-easible with a variety of chemotherapeutic agents, although
solne agents have a l imited ut i l i ty due to either local toxici ty or a rapid removal from the
abdon-rir-ral compartment. The latter is expressed by the peritoneal/plasma area under the
curve (AUC) rat io. \ f lhen high, this means that relat ively more of the drug is present in the
abdon.rir.ral cavitv. This in tuln could in theory result in better efficacy and ultimately
improved survival.  The second lesson learned is that patients with minimal residual disease
following initial cytoreductive surgery are the prir.r.re car.rdidates for IP therapv. This is
explained by the fact that most agents have only a l imited abi l i ty to penetrate dircct ly into
tumor nodulcs. Thirdl l ' ,  the intr insic resistance of tumor cel ls has not becn overcome by II '
therapy clespite the increascd exposure. And fburth, although peritoneal levels of
chemotherapeutic agcnts can be signif icantly higher than obtained intravenously (IV), with
a pcrironcal/pl:rsma AUC lat io which can >1000-fold higher for some of thc agents, the
systenric effects of IP therapy are general ly mild. The thcorct ical concept of IP therapy has
been proven in recent phase II I  tr ials ir-r patients with newly diagnosed ovarian cancer and
minimal residual disease. Patients treatecl with IP cisplat in did signif icantly better in terms
of survival and less systemic side effects. Final ly ir .r  this chapter some of the future
prrspectivcs in IP therapy are brief lv discussed. With the introductior.r of new classes of
potcnt therapeutic agents the combination of cl-roice as f irst- l i r-re treatment nceds to be
acldressed. IP therapy cor"r ld play a key role in the mult idrug approach in ovarian cancer,
due to i ts eff icacy and mild systemic adverse efFects as wil l  bc demonstrate, l  in chapter 2.
Furthen-nore, IP therapy oFfers a potcntial route of administrat ion for non-cvtotoxic agents
such as gene therapy or monoclonal antibodics.
CHAPTER 2
I I)  chemotherapy as a means to increase dose-ir-rtensitv in paticnts with ovarien canccr
has been the focus of studies for decacles as summarized ir-r cl-rapter 1. In chapter 2 the
cfl lcacv. tolerabi l i ty and pharmacokir.ret ics of IP pacl i taxel combined with lV carboplat in
ancl cvclophosphamidc in patients with newly cl iagnosed ovarian cancer is reported. In this
phirsc II  tr i :r l  25 patients with ovarian cancer received lP pacl i taxel (75 mg/mr) on day 1
and 8 in combination with IV carboplat ir .r  (AUC -5) ar.rd cyclophosphamide (750 mg/nr)
on day I for 6 cycles every 4 u'eeks as front- l ine treatment. I)urirrg the f irst treatmcnt cvcle




treatment was tolerated wcl l .  Aciverse events cor-rsistcd mainly of abdominal pain
and hematological toxici t ies, bur were both manageable. Neurctoxicir l 'gradc I/ l l  r .r 'as
reported in l8o/cr and was complctelv reversible ir .r  al l  patients. Myalgia occtrrred in 24o/o of
the patients. After treatmentT6();t t  of the prrt ienrs had no cr. idence of disease. Tl-re median
progressior-r free survivir l  for the u.hole group was 22.7 months. Paticnts with residual
disease afttel surgery (n=10) had a median progrcssion frec strrvival oi l3 months, for the
oprirnal ly debulkcd group (n=15) thc actuarial progression f l-ee surviv:r l  was 609f at 48
"t"t t t i l l i , , .r . ,  
el imir.rarion fr.rn rhe perito.cal cavity fbl lorved f irst orcler kinetics with a
nrean halF-l i fe ( ' I ' t , )  of 25.7 hours.-I 'he plasma kir.ret ics was best described bv a onc
compartmental model. This rcgirnen is effect ive and wcl l- toleratcd arrd al lows :r tr iplc drug
scheclule rvithour compromising dose-intensinl.  About 1000-fold hiehcr ALIC of pacl i taxcl
was achicved IP con-rparcd rvith the systemic comp:rrtment. The abscnce of neurotoxicitv
,rnd acute symproms is in favor of i i )  administrat ion of pacl i taxel,  rvhi le i ts ef l icrcy is
comoarable to IV-based schedules.
CHAPTER 3
Tcrpotecan is a potent inhibitor of DNA to;roisomerasc I in vitro and has slrown
promising activi t) . in relapsecl ovrrr ian cancer. ' l i rpotecrrn inl-r ibi ts topoisonrerasc L an
enzyme rreeded fbr repl icat ion olr l)NA, thus result ing in ccl l  death. Topotccen is prs5,rn. 1' .r
two fcrrnrs deper-rdcr-rt  on pH, narnelv the activc lactorrc, uhich is predominirnt lv prescnt:)t
a pH <4, and the lcss active carboxy forrn. In theorr ' ,  toporec.ln is an.rt tract ive agcnt fbr l [)
therapy, but clata on i ts cl inical ut i l i tv i f  aclnrinisterecl IP ale l imited. ' Ihc feasibi l i tv and
pharmacologl '  of IP topotecar-r is reported in chirpter 3. Fif teen patients with recurrerrt
ovarian cancer wcre entered in this phase I tr ial .  Patients u.ere treated with escalat ing doses
of ropotecan IP (5-30 rng/rnr) adrnini.srered everr '3 vvcek-s f irr  Lrp to 8 cycles. L)uring the
first trcatment c1'cle IP and ;r lasma samples were col lected fbr pham.racoloqical analysis.
L)ose l imit ing toxicitv wi ls.rn acute rc. lct i()11 in one of thrcc patients at thc 30 nrg/rnl
dose level. N' l i ld rbclominal pain was reported in six paticnts ancl was not relatct l  to the dose
level tested. In lVschedules, the dose l imir ing toxicirv of ropotecan is mostlv
nrvelosupprc.ssion. In this stuclv hcmrttological toxici tv was rni ld rvi t l -r  grade [V lerrkopenia
in onc patient, u,hi le two patients expcrier-rccd gracle II  thrombocytopcnia.
Plasnra ievcls of topotccan were deterrnined ciuring thc f irst treriunent clcle. Pl,rsnre
peak lcvels rvere reachccl aftcr 2.7 horrrs (range |.2- 5.4 hours). Both thc maxlnrunl
concentrat ion (C,,, , ,)  and the AU(l werc dose deper.rdent. ' l 'hc rnean peritoneal/plasn.ra
AUC ratio fbr total ropotecan uas 54 t 35, indicating a major pharmacokineric advantagc
fbr lP topotccan. Plasma (onccnirJt ions reqr,r ired fbr cytotoxicitv wcre rcachcd evcn at thc
lowest dose-levels. An intercst irrg obscrvation \\ ' i l .s thc facr thar thc plasnr:r AU(' l  rarirr of
lactone ancl total topotecan incrcased with the topotecan dose i 'on-r l6%r to 55o4,





lcvcls. In these pretreated patients no complete cl inical tumor resp()nses were clbscrvcd, but
of the biochernical ly evaluable paticnts six out of thi l teer.r patier.rts hacl a part ial  respons€,
which is evidence of cl inical eff icacy. This study shows the abi l i tv to adn.r ir .r ister IP
topotccan at dose levels r.rot feasiblc IVwith only mild systemic adverse effects. IP
toPotecan cotr ld t l-rerefbre be an intcrcst ing option for a n-rult idrug approach as f irst- l ine
treatrne nt in oi,arian c: lncer.
CHAPTER 4
l {ecombinanr hurnan inrerletrkin-j  (rhlL-3) i .s r hernaropoetic grou,rh factor ,"vhich l .ras
shown a st inrulat ion of uncommitted blood cel l  progenirors in vitro. ln cl inical studies
cncour:rging results rvere reportecl or-r i rs abi l i ty ro lmeliorare myelostLppression by
acccleratcd bone nrarrow restoration. Ir-r chapter 4 the results of the f irst randomized
cl inical tr ial  with rhl l .-3 are reportecl.  In this mult icenter study 185 patier.rts with aclvarrcct l
ovarian cancer receivir-rg con'rbination chemothcrapr.,  carboplat in (AIJC =4) and
cvc lophosphanr ic lc  (750 nrq / rn r )  l \ ' on  dav  1 ,  evcr r '3  wccks  fb r  6  q 'c les  were  randomized
to rcccive rhl l .-3 (5 pg/kg) or a placebo evcry cvclc as r once dai l '  sr-Lbcutaneous
in iec t ion  on  dr tvs  3 -12 . ' l ' he  a im o f  thc  s rudy  was to  de termine whether  rh lL -3  reduces
bone marrow depression and improvcs adherence to a chemotherapeuric schedule ir-r this ser
of patients. Although sigr.r i f icant cffccts had been observed in phase I/ l l  tr ials with rhlL-3,
rtclherence to rhe chemotherapcr.rt ic rcginren and the rnean chemotherepr.cvcle lcngth dicl
not dif frer bent 'ccu the two groLlps. Thcrc was alscl no dif ference observed ln rurlor rcspon.se
rate and meclietr survival at 2zi months betwecn thc eroups. The nrLnrber o[side eff 'ects
observecl - prir .nari ly al lergic reacrions, f lu- l ike symproms and fever - u,ere highe r in rhc
rh l l , -3  g roup. ' l ' h is  led  to  21  d isconr inuat ions  in  tha t  g roup as  compared to  one in  the
pl:rcebo group. Oornparedwith the placebo group, t l .re rhl l-3 group had higher (p<0.00 l)
platelet counrs ()n t lrrv 1 of cycles 2 to (r.  No dif ference, however, was obscned ir-r thc
uumber of p:rt icnts rvith nacl ir  \X/H() grade iV thronrbocytoper-r ia or in rhc number of
platelet trausfirsiotrs. Lcukocytc counts benveen rhe two groups dif l i red only in the f lrsr 2
cvcles. ' I 'he leukocyte nadir occurrcd carl icr in the rhl l .-3 grolrp, on day 12, as compared ro
cla1, l5 in the placebo group (p=0.906). Leukoci ' tes and netrtrophi ls were only sigr.r i f icantlv
higher in thc rhlL-3 group on dav I of cvcle 2. ' l 'hus, although rhl l-3 had st imulatory
hemirtopoiet ic c-ffects i t  resulted neither in a redr.rct ion of platelet rrrrnsf irsions nor in an
itnprovctnetrt  of adherence ro rhe chemotherlpeutic schcdulc. Thcrc rvcre rnorc sicle cf-fccts
obscrvccl in thc rhl l .-3 group rharr in the placebo group. Because of i ts l imited cff icts rnd
its toxicity prof i lc, t l ' rc use of rhl l .-3 at a dose of 5 Fg/kgiday is therefirre r.rot of cl ir .r ical




Since thcir inrroclrrct ion, he matopoie t ic growth factors, such as granuloo'te-
macrophagc colonv st imulrrt ing Facror (GM-(-SF), have fbrLnd a role, part icr.r lar lv in the
field of oncology. CiM-CSF has been shown to st imulate the prol i ferat ion and maturation
of myeloicl cel ls in the marrorv encl bloocl.  Vhen ( l l r . '1-( lSl '  is aclnrinisterecl .r t  dr i l l  t los.. . t f
5-10 pg/kg subcutaneously to paticnts, wl 'ro have received cl, totoxic therapl 'which induces
signif icant leucopenir,  rhe white blood cel l  nadir is not alterecl but r l .re duration of
leucopenia is shorrened. ( lN{-CSF is also rLsed fbr hematol.roict ic srcrr.L cel l  nrobi l izet ion aucl
subsequent harvesting for high-dose chernotl .rerapy with henratopoict ic stenr cel l
tr i rnsplantat ion. Clhapter 5 locuses on ql lest ions lbout i ts use in the diFferent sctt int\ .
First ly, in the manirgement of drug-inducecl neutropenic fever, a potential scrious
complication of chernotherapy. With the avai lablc clata, the use of CM-CSF routinclv as an
ad.juncr to rnribioric theraPv in this sett ing is not rccommenclcd. However, i t  is ntt t
precluded that a subgroup of patients mav benefl t  f l 'orn the applicarion oF(iM-(lSl-.
Seconcl ly, CSFs mav pl:rv a role in the use of dosc-intense chcmotl ' rcrapv as rtel l  as
aurologous stem cel l  tr i rnsplantat ior-r.  Tl-rey have shown to shortcn thc clt trarion ot '
neutropcnia ancl reduce infections irr patients urrdcrgoing high dose chemothcrapv rvith
srcrn cel l  reinf irsion. CSFs mighr be irscd as rrn ad.jur-rct to al loqcnic rrnd:rutologous stenr
cel l  transplantat ion, both fbr mobil izat ion and to cnhance hematopoict ic rccovery
fol lolving srcrn cel l  reinfusiorr.  Final lr-,  an cconomic rnoclel is describccl to rrssess the
potcntial savings from a cl ir t ical appl icat ion of ( lSFs in dif fcrcnt scrt ings.
CHAPTER 6
Measuring responses in paticnts wit l-r  ovarian cancer is a dif l lcult  task. Most patients
have disease that cannot bc adequately t-nonitored u' i t l ' r  computccl tonrograP]l ' ,  MRI or
ultrasound. In the pal l iat ivc sett ing p:rt ients are the refbre often treatccl unti l  cl inicir l
progressiorr,  wit l-rout perforn-r ing standardizecl tumol '  mexsulcnrunts Jt srr ict intervels.
N'[r l l i tor ing of (]A- I25 serr.Lrn levcis is an attract ive altertrrrt ive in ovari:rn c: lnccr, bccattse ir
is clevated in most parienrs with adr.anced cl iscase and i ts course is well  correl:r tecl u. i th
tumor growth or rcgrcssion. An orher way to cr.alurrtc responses is thr 'calctt lrr t ion of the
rate of changc of CA-125 scrur-n lcvels over t ime. This rncrhod can bc used to crlculrte 11
CA-125 doubling t ime or hrr l f- l iFe, rurd enables a biochcrnicrl  responsc deflnit ion u'hich is
der-rendcnt on the t ime bctrveen l l-re: lsurclncnrs ancl less ou alrsolute valucs.
ln chapter (r the cffect of or:r l  etoposide as pal l iat ive chen'rotherapv on ( iA-125 serttrn
lcvels was evrluated using r l-r is principlc to assess eff icacy i l r  l7 patients rvith recttrrent
ovirr ian cancer. A prolor-rg.-cl scheclLrle of lorv close clai ly oral etoposide h:rs proven to tre an
eFfectivc second-l inc rrerrment, also in paticnts with plat inLrni rcsistance. In this stLrdr", ( lA-
l l5 levcl.s af icr 4 course-s \\ 'ere c()nlp:rrccl to be.sel inc (CA-115 rario). The r:rtc of changc r>f
( lA 125 (s = slope of the exponcntial rcgression curve) cluring the f lrst 4 courses rv,ts





Although thc biochemical response rate was modest (12.5o/o), a decrease of s rvas
observecl in 14116 patients (p = 0.02). ' l 'he n.rean change of s represented an increase of
r-r-rean dotrblir-rg tirne frorn 52 to 693 davs. No patients were withdrawn because of toxicity.
General malaise, nausea, diarrhea and anemia were the most important siclc-effects. At the
given dose schedule, oral etoposidc shows activi ty ir-r advar-rced ovarian cancer iFthe rate of
change of CA-125 is used as a mc:lsure of act ivi ty.
CHAPTER 7
Vith the presence of hormone receptors in a high percenrage of ovarian cancer,
hormonal therapv is irn interesting option in the treatmcnt olrovarian cancer. ln mice,
endogcnous gonadotropins, which st imulatc the theca granulosa cel ls under physiological
concl i t ions, play a role in t l ' re carcinoger-resis of epithcl ial  ovarian cancer. lnject ing mice with
a luteinising hormone releasing honnone (LHRH) analog showed suppressior.r of the
development of ovarian tumors. 'Ihmoxifen proved effictive in a stem cell assay ir-r about
40oi ofthe ovarian cancer cel l  l ines tested, btrt  the cl inical eff icacy ofthis antiesrrogen is
reportecl to be from 0 to 25oro. In ch,rpter 7 rhe rcsults are reported of 25 patients rvith
recu.r.rent, chemotherapy rcsistrrnt ovarian cancer who were treated with goserel ir-r (LHRH-
analog) ar.rd tamoxifcn unti l  cl inical or serological (serurn CA-|25 levels) evidence of
pnrgrcssion. Paticnts received a combination of goscrel in 3.6 rng strbcurancous ()rrce cvcry
fbur wceks and oral tamoxifetr 20 mg dai lv. Suppression of gonadotropin ar-rcl prol:rct in
levels ir-r this group wcrc compared with a second group of tcn parienrs treated with
decapeptvl for the same indication. l-he cornbination of tamoxifen with goserel in was well
tolerated. ' l 'he n-recl ian progrcssion free survival amounted to f ive (r:rnge 2-96+) monrhs
and overal l  survival to eight (rangc 3-96+) nronths. One of t l .rc rcsponding patients is st i l l
al ive without progrcssion at l0 vears. ' I 'he r.r.rediar.r levels of i .H and FSH were r.r.r :rrkedly
su;rpressccl during trcatnrent rvi th this combinarion, ro respecrively 2.6olt  and3.7ok of
basel ine valucs. Durins trcatnrent with decapepryl thc LH levels were suppressed to a
similar extent, but thc rcsult ing FSH levels were signif icantly higher. ' [ 'hese results confirm
tl ' rat combination hormonal therapy in patients with relapsed chcnrotherapl '  lesistant
ovarian cl l l lcer cannot be recotnmcnded as standard t l-rerapv, but rnay resulr in [ong tern-r
survival ir .r  i r .rdividual paticnts with I i t t le or: no sicle-effecrs.
FUTURE PERSPECTIVES
Final lv, somc f i t ture perspectives of new thcrlpv options are cl iscussecl in a nutshcl l .
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